Checkpoint Price Earnings Ratio from 2010 to 2024

CKPT Stock  USD 4.03  0.28  7.47%   
Checkpoint Therapeutics Price Earnings Ratio yearly trend continues to be comparatively stable with very little volatility. Price Earnings Ratio will likely drop to -0.87 in 2024. From the period from 2010 to 2024, Checkpoint Therapeutics Price Earnings Ratio quarterly data regression had mean square error of  3.13 and mean deviation of  3.14. View All Fundamentals
 
Price Earnings Ratio  
First Reported
2010-12-31
Previous Quarter
(0.83)
Current Value
(0.87)
Quarterly Volatility
3.45604251
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Checkpoint Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Checkpoint Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 102.1 K, Depreciation And Amortization of 159.5 K or Interest Expense of 5.2 M, as well as many indicators such as Price To Sales Ratio of 438, Dividend Yield of 0.0 or Days Sales Outstanding of 168. Checkpoint financial statements analysis is a perfect complement when working with Checkpoint Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Checkpoint Therapeutics Correlation against competitors.
For more information on how to buy Checkpoint Stock please use our How to Invest in Checkpoint Therapeutics guide.

Latest Checkpoint Therapeutics' Price Earnings Ratio Growth Pattern

Below is the plot of the Price Earnings Ratio of Checkpoint Therapeutics over the last few years. It is Checkpoint Therapeutics' Price Earnings Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Checkpoint Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Price Earnings Ratio10 Years Trend
Slightly volatile
   Price Earnings Ratio   
       Timeline  

Checkpoint Price Earnings Ratio Regression Statistics

Arithmetic Mean(5.41)
Coefficient Of Variation(63.85)
Mean Deviation3.14
Median(6.44)
Standard Deviation3.46
Sample Variance11.94
Range8.117
R-Value0.87
Mean Square Error3.13
R-Squared0.76
Significance0.000025
Slope0.67
Total Sum of Squares167.22

Checkpoint Price Earnings Ratio History

2024 -0.87
2023 -0.83
2022 -0.67
2021 -4.18
2020 -6.44
2019 -2.47
2018 -1.43

About Checkpoint Therapeutics Financial Statements

Checkpoint Therapeutics shareholders use historical fundamental indicators, such as Price Earnings Ratio, to determine how well the company is positioned to perform in the future. Although Checkpoint Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Checkpoint Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Checkpoint Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Price Earnings Ratio(0.83)(0.87)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Checkpoint Stock Analysis

When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.